Taken together, the results of these trials demonstrate a significant benefit for both immunotherapy with anti-PD1 (nivolumab, pembrolizumab) and targeted therapies (dabrafenib/trametinib) in the adjuvant setting in patients with stage III and/or stage IV (limited to nivolumab) melanoma patients. The gene discussed is PDCD1; the disease is melanoma.